China SXT Pharmaceuticals, Inc. SXTC
Annual
Quarterly
FY2026 · ended Mar 31, 2026 · Revenue $1.14M, -34.6% YoY · Filed Jul 1, 2026
China SXT Pharmaceuticals, Inc. (SXTC) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $1.1 million and a net loss of $6.2 million. As of Mar 31, 2026 it held $28.2 million in cash and investments and $1.1 million in total debt.
Revenue
$1.14M
-34.6% vs prior year
Net income
$-6.21M
-87.8% vs prior year
Operating cash flow
$-4.02M
-71.3% vs prior year
Free cash flow
$-2.35M
-392.2% vs prior year
EPS
$-9.13
+97.4% vs prior year
Dividend per share
None
Shares outstanding
958,077
Net cash
$27.05M
FY 2026
Operating margin
-625.9%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SXTC (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Virgin Islands, British
- Headquarters
- Taizhou
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1723980
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $1.9M | $2.0M | $2.6M |
| Operating income | -$7.1M | -$2.7M | -$2.5M | -$5.6M | -$5.2M |
| Net income | -$6.2M | -$3.3M | -$3.1M | -$5.9M | -$5.7M |
| Diluted EPS | -$9.13 | -$348.17 | -$4,285.66 | -$177.84 | — |
| Operating cash flow | -$4.0M | -$2.3M | -$1.9M | -$80,757 | $268,293 |
| Free cash flow | — | -$2.3M | — | — | — |
| Total assets | $34.8M | $21.7M | $23.1M | $29.6M | $33.5M |
| Total liabilities | $5.0M | $6.2M | $9.2M | $14.9M | $17.1M |
| Stockholders' equity | $29.7M | $15.4M | $13.9M | $14.7M | $16.1M |
| Cash and investments | $28.2M | $18.1M | $12.1M | — | — |
| Total debt | $1.1M | $1.7M | $1.4M | $599,228 | $11,404 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 21, 2026 | Oct 21, 2026 |
| 6-K | Current report (foreign issuer) | Oct 9, 2026 | Oct 9, 2026 |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Oct 8, 2026 | Oct 8, 2026 |
| 6-K | Current report (foreign issuer) | Aug 28, 2026 | Aug 28, 2026 |
| 6-K | Current report (foreign issuer) | Jul 24, 2026 | Jul 24, 2026 |
All 169 China SXT Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.